Purpose | Patients | Evaluations | Perceived Effectiveness |
---|---|---|---|
Systemic lupus erythematosus | 22,740 | 788 | |
Rheumatoid arthritis | 3,657 | 397 | |
Mixed connective tissue disease | 642 | 85 | |
Undifferentiated connective tissue disease | 448 | 59 | |
Subacute cutaneous lupus erythematosus | 180 | 15 |
Common side effects
Side effect | Patients | Percentage |
---|---|---|
Nausea | 116 | |
Diarrhea | 59 | |
Blurry vision | 45 | |
Headaches | 34 | |
Stomach pain | 29 | |
Dizziness | 21 |
Side effect severity
Severity | Evaluations | Percentage |
---|---|---|
Severe | 173 | |
Moderate | 218 | |
Mild | 301 | |
None | 719 |
Member evaluations
psyclops
evaluated on Oct 01, 2021
- Perceived effectiveness for systemic lupus erythematosus: Major
- Side effects: None
origin
evaluated on Jan 09, 2019
- Perceived effectiveness for Sjogren's syndrome: Can't tell
- Side effects: Mild
alf53
evaluated on Jun 29, 2001
- Perceived effectiveness for mixed connective tissue disease: Slight
- Side effects: None